Skip to main content
Vita 34 AG logo

Vita 34 AG — Investor Relations & Filings

Ticker · V3V ISIN · DE000A0BL849 LEI · 529900OEWA4GSZEZ4P40 F Human health and social work activities
Open in API
Filings indexed 794 across all filing types
Latest filing 2022-09-28 Director's Dealing
Country DE Germany
Listing F V3V

About Vita 34 AG

https://www.vita34.de/en/

Vita 34 AG is a biobank specializing in the cryopreservation of stem cells derived from umbilical cord blood and tissue. Established in 1997 as the first private cord blood bank in Europe, the company offers services for the long-term storage of perinatal stem cells for potential future medical applications. The service portfolio includes providing collection kits for childbirth, handling logistics, processing the biological material, and storing the stem cell deposits under cryogenic conditions. These services are offered to expectant parents as a form of private medical provision for their child and family. As part of the Famicord Group, Vita 34 is also involved in research and development related to cell-based therapies.

Recent filings

Filing Released Lang Actions
EQS-DD: Vita 34 AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains sections detailing 'Details of the person discharging managerial responsibilities' and 'Details of the transaction(s)' involving the acquisition of shares by a person closely associated with a director. This directly matches the definition for Director's Dealing (DIRS). The document structure and content confirm this classification, and it is not a general announcement of a report (RPA/RNS) nor a comprehensive financial filing.
2022-09-28 English
Vita 34 records moderate upward trend in the second quarter
Earnings Release Classification · 100% confidence The document explicitly states it covers results for the 'second quarter' and 'first half of the year' (H1 2022 vs H1 2021), detailing revenues, EBITDA, and other key financial metrics. It uses the keyword 'Half Year Report' in the DGAP header. This content structure—a summary of financial performance for a period shorter than a full year—is characteristic of an Interim/Quarterly Report. Although it is presented as a news release (DGAP-News), the core content is the comprehensive financial summary for the half-year period, making 'IR' (Interim / Quarterly Report) the most appropriate classification over a simple 'ER' (Earnings Release) or 'RPA' (Report Publication Announcement), as it contains the detailed figures and management discussion, not just an announcement that a report exists. The document length (8768 chars) is substantial enough to contain the report's substance. H1 2022
2022-08-30 English
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2022 bis zum 30.06.2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halbjahresfinanzbericht' (Half-Year Financial Report) for Vita 34 AG covering the period from 01.01.2022 to 30.06.2022. It contains detailed financial statements, management discussion and analysis (Konzern-Zwischenlagebericht), segment reporting, and balance sheet data. It is a comprehensive interim report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-30 German
Half-yearly financial report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT' and covers the period from January to June 2022. It contains comprehensive financial data, including a 'Group Key Figures' table, 'Condensed Interim Consolidated Financial Statements', and a 'Management Report'. It is clearly a formal interim financial report, not an announcement or a summary, and meets the criteria for an Interim/Quarterly Report. H1 2022
2022-08-30 English
Vita 34 lowers sales and earnings guidance due to IFRS 15 effect and accelerated restructuring measures
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc' announcement dated August 29, 2022, explicitly titled 'Vita 34 lowers sales and earnings guidance due to IFRS 15 effect and accelerated restructuring measures'. It details adjustments to the full-year forecast for consolidated sales and EBITDA. This type of announcement, which provides key financial highlights and guidance revisions outside of a full quarterly or annual report, aligns best with the 'Earnings Release' (ER) definition, which covers initial announcements of periodical financial results and key highlights. Although it's a guidance revision rather than a standard earnings release, it serves the same function of immediately informing the market of updated financial expectations. It is too specific to be a general Regulatory Filing (RNS) and is not a full report (10-K or IR). FY 2022
2022-08-29 English
Report Publication Announcement 2022
Report Publication Announcement Classification · 100% confidence The document is titled "Preliminary announcement of the publication of financial reports..." and explicitly states that the company "hereby announces that the following financial reports shall be disclosed," providing future disclosure dates (August 30, 2022) and links to where the reports will be available. This structure—announcing the future release of a report rather than containing the report itself—fits the definition of a Report Publication Announcement (RPA). The document length is short (1943 chars), supporting the 'MENU VS MEAL' rule, which dictates classifying announcements of reports as RPA instead of the report type (like IR).
2022-08-23 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.